Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Miravirsen

Generic Name: Miravirsen

Drug Type: Biotech

CAS Number: 1072874-90-8

Unique Ingredient Identifier: Q083AJW7VS

Overview

Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.

Background

Miravirsen has been investigated for the treatment of Hepatitis C and Hepatitis C, Chronic.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection

Phase 2

Posted: 2013/06/07

Sponsor:

Santaris Pharma A/S

ID:NCT01872936

Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Phase 2

Posted: 2012/11/16

Sponsor:

Santaris Pharma A/S

ID:NCT01727934

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

Phase 1

Completed

Posted: 2012/07/20

Sponsor:

Santaris Pharma A/S

ID:NCT01646489

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

Phase 2

Completed

Posted: 2010/09/13

Sponsor:

Santaris Pharma A/S

ID:NCT01200420

SPC3649 Multiple Dose Study in Healthy Volunteers

Phase 1

Completed

Posted: 2009/09/18

Sponsor:

Santaris Pharma A/S

ID:NCT00979927

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy